MX2019006426A - Reguladores de tau, y composiciones y metodos para su administracion. - Google Patents
Reguladores de tau, y composiciones y metodos para su administracion.Info
- Publication number
- MX2019006426A MX2019006426A MX2019006426A MX2019006426A MX2019006426A MX 2019006426 A MX2019006426 A MX 2019006426A MX 2019006426 A MX2019006426 A MX 2019006426A MX 2019006426 A MX2019006426 A MX 2019006426A MX 2019006426 A MX2019006426 A MX 2019006426A
- Authority
- MX
- Mexico
- Prior art keywords
- delivery
- compositions
- methods
- tau modulators
- tau
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002068 genetic effect Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
- C12N15/8645—Adeno-associated virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Marine Sciences & Fisheries (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente descripción se encuentra en el campo de métodos de diagnóstico y productos terapéuticos para la enfermedad de Alzheimer que concierne a la regulación génica in vivo de un gen responsable de la enfermedad.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662428871P | 2016-12-01 | 2016-12-01 | |
US201762450895P | 2017-01-26 | 2017-01-26 | |
US201762466198P | 2017-03-02 | 2017-03-02 | |
US201762500807P | 2017-05-03 | 2017-05-03 | |
US201762584342P | 2017-11-10 | 2017-11-10 | |
PCT/US2017/064181 WO2018102665A1 (en) | 2016-12-01 | 2017-12-01 | Tau modulators and methods and compositions for delivery thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019006426A true MX2019006426A (es) | 2019-08-14 |
Family
ID=62239970
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019006426A MX2019006426A (es) | 2016-12-01 | 2017-12-01 | Reguladores de tau, y composiciones y metodos para su administracion. |
Country Status (11)
Country | Link |
---|---|
US (2) | US11504389B2 (es) |
EP (1) | EP3548616A4 (es) |
JP (2) | JP7292204B2 (es) |
KR (1) | KR20190085529A (es) |
CN (1) | CN110214184A (es) |
AU (1) | AU2017367722B2 (es) |
BR (1) | BR112019010014A2 (es) |
CA (1) | CA3043635A1 (es) |
IL (1) | IL266862B2 (es) |
MX (1) | MX2019006426A (es) |
WO (1) | WO2018102665A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020072684A1 (en) * | 2018-10-02 | 2020-04-09 | Sangamo Therapeutics, Inc. | Engineered genetic modulators |
US20200101133A1 (en) * | 2018-10-02 | 2020-04-02 | Sangamo Therapeutics, Inc. | Methods and compositions for modulation of tau proteins |
MX2021012527A (es) * | 2019-04-12 | 2022-01-06 | Encoded Therapeutics Inc | Composiciones y métodos de administración de terapéuticos. |
CA3137368A1 (en) | 2019-04-23 | 2020-10-29 | Sangamo Therapeutics, Inc. | Modulators of chromosome 9 open reading frame 72 gene expression and uses thereof |
CN114981442A (zh) | 2019-12-04 | 2022-08-30 | 桑格摩生物治疗股份有限公司 | 用于生产重组aav的新颖组合物及方法 |
UY39036A (es) * | 2020-01-22 | 2021-08-31 | Sangamo Therapeutics Inc | Factores de transcripción de proteína de dedos de zinc para represión de la expresión tau |
WO2022009987A1 (en) * | 2020-07-09 | 2022-01-13 | Modalis Therapeutics Corporation | Method for treating alzheimer's disease by targeting mapt gene |
CN112640847B (zh) * | 2020-12-30 | 2022-12-13 | 重庆医科大学附属第一医院 | 一种内源性癫痫发作动物模型及其构建方法 |
Family Cites Families (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4946787A (en) | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US5049386A (en) | 1985-01-07 | 1991-09-17 | Syntex (U.S.A.) Inc. | N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US6140466A (en) | 1994-01-18 | 2000-10-31 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
ATE310812T1 (de) | 1994-01-18 | 2005-12-15 | Scripps Research Inst | Derivate von zinkfingerproteinen und methoden |
EP0752005B1 (en) | 1994-03-23 | 2008-10-08 | Ohio University | Compacted nucleic acids and their delivery to cells |
JP4118327B2 (ja) | 1994-08-20 | 2008-07-16 | ゲンダック・リミテッド | Dna認識のための結合タンパク質におけるまたはそれに関連する改良 |
GB9824544D0 (en) | 1998-11-09 | 1999-01-06 | Medical Res Council | Screening system |
US5789538A (en) | 1995-02-03 | 1998-08-04 | Massachusetts Institute Of Technology | Zinc finger proteins with high affinity new DNA binding specificities |
US5925523A (en) | 1996-08-23 | 1999-07-20 | President & Fellows Of Harvard College | Intraction trap assay, reagents and uses thereof |
GB9710809D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
GB9710807D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
US6479626B1 (en) | 1998-03-02 | 2002-11-12 | Massachusetts Institute Of Technology | Poly zinc finger proteins with improved linkers |
ES2324540T3 (es) | 1998-05-27 | 2009-08-10 | Genzyme Corporation | Vectores aav para la fabricacion de medicamentos para la administracion potenciada por conveccion. |
US6140081A (en) | 1998-10-16 | 2000-10-31 | The Scripps Research Institute | Zinc finger binding domains for GNN |
US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
US6599692B1 (en) | 1999-09-14 | 2003-07-29 | Sangamo Bioscience, Inc. | Functional genomics using zinc finger proteins |
US6453242B1 (en) | 1999-01-12 | 2002-09-17 | Sangamo Biosciences, Inc. | Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites |
US7013219B2 (en) | 1999-01-12 | 2006-03-14 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
WO2001040798A2 (en) | 1999-12-06 | 2001-06-07 | Sangamo Biosciences, Inc. | Methods of using randomized libraries of zinc finger proteins for the identification of gene function |
EP1254369B1 (en) | 2000-02-08 | 2010-10-06 | Sangamo BioSciences, Inc. | Cells for drug discovery |
US20020061512A1 (en) | 2000-02-18 | 2002-05-23 | Kim Jin-Soo | Zinc finger domains and methods of identifying same |
AU2001263155A1 (en) | 2000-05-16 | 2001-11-26 | Massachusetts Institute Of Technology | Methods and compositions for interaction trap assays |
JP2002060786A (ja) | 2000-08-23 | 2002-02-26 | Kao Corp | 硬質表面用殺菌防汚剤 |
WO2002046412A2 (en) | 2000-12-07 | 2002-06-13 | Sangamo Biosciences, Inc. | Regulation of angiogenesis with zinc finger proteins |
GB0108491D0 (en) | 2001-04-04 | 2001-05-23 | Gendaq Ltd | Engineering zinc fingers |
US7182944B2 (en) | 2001-04-25 | 2007-02-27 | The United States Of America As Represented By The Department Of Health And Human Services | Methods of increasing distribution of nucleic acids |
JP2005500061A (ja) | 2001-08-20 | 2005-01-06 | ザ スクリップス リサーチ インスティテュート | Cnnについての亜鉛フィンガー結合ドメイン |
JP4769417B2 (ja) | 2001-12-17 | 2011-09-07 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | アデノ随伴ウイルス(aav)血清型9の配列、それを含むベクターおよびその使用 |
US7074596B2 (en) | 2002-03-25 | 2006-07-11 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synthesis and use of anti-reverse mRNA cap analogues |
EP1635763B1 (en) * | 2003-06-09 | 2012-08-08 | Alnylam Pharmaceuticals Inc. | Method of treating neurodegenerative disease |
US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
US8409861B2 (en) | 2003-08-08 | 2013-04-02 | Sangamo Biosciences, Inc. | Targeted deletion of cellular DNA sequences |
WO2005030959A1 (ja) * | 2003-09-25 | 2005-04-07 | Chiba-Prefecture | 神経芽細胞腫予後診断のためのマイクロアレイと神経芽細胞腫予後診断方法 |
US20060239966A1 (en) | 2003-10-20 | 2006-10-26 | Tornoee Jens | In vivo gene therapy of parkinson's disease |
BRPI0516463B1 (pt) | 2004-10-05 | 2021-05-11 | Genzyme Corporation | sistema de entrega de um ou mais materiais |
EP1877583A2 (en) | 2005-05-05 | 2008-01-16 | Arizona Board of Regents on behalf of the Unversity of Arizona | Sequence enabled reassembly (seer) - a novel method for visualizing specific dna sequences |
EP1928557B1 (en) | 2005-08-23 | 2018-06-06 | The Regents of The University of California | Reflux resistant cannula and system for chronic delivery of therapeutic agents using convection-enhanced delivery |
EP2019683B2 (en) | 2006-04-25 | 2022-08-03 | The Regents of The University of California | Administration of growth factors for the treatment of cns disorders |
CA2651494C (en) | 2006-05-25 | 2015-09-29 | Sangamo Biosciences, Inc. | Engineered cleavage half-domains |
US7837668B2 (en) | 2006-10-10 | 2010-11-23 | Ceregene, Inc. | Needle assembly for use in delivering precise dosages of proteinaceous pharmaceutical compositions and methods for use of same |
PL2167523T3 (pl) | 2007-06-19 | 2014-12-31 | Univ Louisiana State | Synteza i zastosowanie anty-odwrotnych tiofosforanowych analogów kapu matrycowego RNA |
WO2009042163A2 (en) | 2007-09-27 | 2009-04-02 | Sangamo Biosciences, Inc. | Rapid in vivo identification of biologically active nucleases |
CA2726768C (en) | 2008-06-10 | 2016-09-06 | Sangamo Biosciences, Inc. | Methods and compositions for generation of bax- and bak-deficient cell lines |
KR20160015400A (ko) | 2008-08-22 | 2016-02-12 | 상가모 바이오사이언스 인코포레이티드 | 표적화된 단일가닥 분할 및 표적화된 통합을 위한 방법 및 조성물 |
US20110016539A1 (en) | 2008-12-04 | 2011-01-20 | Sigma-Aldrich Co. | Genome editing of neurotransmission-related genes in animals |
KR20100080068A (ko) * | 2008-12-31 | 2010-07-08 | 주식회사 툴젠 | 신규한 징크 핑거 뉴클레아제 및 이의 용도 |
EP2206723A1 (en) | 2009-01-12 | 2010-07-14 | Bonas, Ulla | Modular DNA-binding domains |
UA107571C2 (xx) | 2009-04-03 | 2015-01-26 | Фармацевтична композиція | |
US9234016B2 (en) | 2009-07-28 | 2016-01-12 | Sangamo Biosciences, Inc. | Engineered zinc finger proteins for treating trinucleotide repeat disorders |
KR20120097484A (ko) | 2009-07-31 | 2012-09-04 | 에트리스 게엠베하 | 단백질 발현을 위한 비변형된 뉴클레오티드 및 변형된 뉴클레오티드의 조합을 가진 rna |
US8956828B2 (en) | 2009-11-10 | 2015-02-17 | Sangamo Biosciences, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
US20110135613A1 (en) * | 2009-12-03 | 2011-06-09 | The J. David Gladstone Institutes | Methods for treating apolipoprotein e4-associated disorders |
PT2534173T (pt) | 2010-02-08 | 2019-10-31 | Sangamo Therapeutics Inc | Semidomínios de clivagem manipulados |
LT2566972T (lt) | 2010-05-03 | 2020-03-10 | Sangamo Therapeutics, Inc. | Kompozicijos, skirtos cinko pirštu modulių susiejimui |
EP3156062A1 (en) | 2010-05-17 | 2017-04-19 | Sangamo BioSciences, Inc. | Novel dna-binding proteins and uses thereof |
US9322023B2 (en) | 2011-10-06 | 2016-04-26 | Cornell University | Constructs and methods for the assembly of biological pathways |
JP6144691B2 (ja) | 2011-11-16 | 2017-06-07 | サンガモ セラピューティクス, インコーポレイテッド | 修飾されたdna結合タンパク質およびその使用 |
CN108285491B (zh) | 2012-02-29 | 2021-08-10 | 桑格摩生物科学股份有限公司 | 治疗亨廷顿氏病的方法和组合物 |
EP2931899A1 (en) * | 2012-12-12 | 2015-10-21 | The Broad Institute, Inc. | Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof |
CN105264091B (zh) * | 2013-03-14 | 2020-02-28 | Ionis制药公司 | 用于调节tau表达的组合物和方法 |
CN105683376A (zh) | 2013-05-15 | 2016-06-15 | 桑格摩生物科学股份有限公司 | 用于治疗遗传病状的方法和组合物 |
AU2014274840B2 (en) | 2013-06-05 | 2020-03-12 | Duke University | RNA-guided gene editing and gene regulation |
TWI702046B (zh) | 2013-07-19 | 2020-08-21 | 美商Ionis製藥公司 | 用於調節τ蛋白表現之組合物 |
US9359599B2 (en) * | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
WO2015038958A1 (en) | 2013-09-13 | 2015-03-19 | California Institute Of Technology | Selective recovery |
EP3080611B1 (en) | 2013-12-13 | 2018-11-14 | The General Hospital Corporation | Soluble high molecular weight (hmw) tau species and applications thereof |
WO2015143046A2 (en) | 2014-03-18 | 2015-09-24 | Sangamo Biosciences, Inc. | Methods and compositions for regulation of zinc finger protein expression |
WO2015153760A2 (en) | 2014-04-01 | 2015-10-08 | Sangamo Biosciences, Inc. | Methods and compositions for prevention or treatment of a nervous system disorder |
JP2017515819A (ja) | 2014-05-08 | 2017-06-15 | サンガモ セラピューティクス, インコーポレイテッド | ハンチントン病を処置するための方法および組成物 |
WO2015188056A1 (en) * | 2014-06-05 | 2015-12-10 | Sangamo Biosciences, Inc. | Methods and compositions for nuclease design |
US20170035860A1 (en) * | 2015-04-02 | 2017-02-09 | Alexander C. Flynn | Compositions and methods for treatment of neurogenerative diseases |
WO2017011556A1 (en) | 2015-07-13 | 2017-01-19 | The General Hospital Corporation | Rare phosphorylated high molecular weight (hmw) tau species that are involved in neuronal uptake and propagation and applications thereof |
KR20180069054A (ko) | 2015-10-28 | 2018-06-22 | 상가모 테라퓨틱스, 인코포레이티드 | 간-특이적 작제물인, 인자 viii 발현 카세트 및 이의 사용 방법 |
WO2017197141A2 (en) | 2016-05-13 | 2017-11-16 | Sangamo Therapeutics, Inc. | Targeted treatment of androgenic alopecia |
WO2018039448A1 (en) | 2016-08-24 | 2018-03-01 | Sangamo Therapeutics, Inc. | Engineered target specific nucleases |
BR112019003100A2 (pt) * | 2016-08-24 | 2019-07-09 | Sangamo Therapeutics Inc | regulação da expressão gênica usando nucleases manipuladas |
WO2018039471A2 (en) | 2016-08-25 | 2018-03-01 | Trustees Of Boston University | Synthetic transcriptional and epigenetic regulators based on engineered, orthogonal zinc finger proteins |
EP3509645A4 (en) | 2016-09-07 | 2020-06-17 | Sangamo Therapeutics, Inc. | MODULATION OF LIVER GENES |
US11371023B2 (en) | 2016-11-22 | 2022-06-28 | Wisconsin Alumni Research Foundation | Artificial transcription factors and uses thereof |
US20200101133A1 (en) | 2018-10-02 | 2020-04-02 | Sangamo Therapeutics, Inc. | Methods and compositions for modulation of tau proteins |
WO2020072684A1 (en) | 2018-10-02 | 2020-04-09 | Sangamo Therapeutics, Inc. | Engineered genetic modulators |
UY39036A (es) | 2020-01-22 | 2021-08-31 | Sangamo Therapeutics Inc | Factores de transcripción de proteína de dedos de zinc para represión de la expresión tau |
-
2017
- 2017-12-01 KR KR1020197016870A patent/KR20190085529A/ko active IP Right Grant
- 2017-12-01 BR BR112019010014A patent/BR112019010014A2/pt unknown
- 2017-12-01 AU AU2017367722A patent/AU2017367722B2/en active Active
- 2017-12-01 IL IL266862A patent/IL266862B2/en unknown
- 2017-12-01 JP JP2019529263A patent/JP7292204B2/ja active Active
- 2017-12-01 MX MX2019006426A patent/MX2019006426A/es unknown
- 2017-12-01 CA CA3043635A patent/CA3043635A1/en active Pending
- 2017-12-01 US US15/828,931 patent/US11504389B2/en active Active
- 2017-12-01 WO PCT/US2017/064181 patent/WO2018102665A1/en unknown
- 2017-12-01 CN CN201780084345.1A patent/CN110214184A/zh active Pending
- 2017-12-01 EP EP17876620.0A patent/EP3548616A4/en active Pending
-
2022
- 2022-10-13 US US18/046,327 patent/US20230270774A1/en active Pending
-
2023
- 2023-03-29 JP JP2023053704A patent/JP2023078446A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2023078446A (ja) | 2023-06-06 |
AU2017367722B2 (en) | 2024-02-01 |
WO2018102665A1 (en) | 2018-06-07 |
BR112019010014A2 (pt) | 2019-08-20 |
AU2017367722A1 (en) | 2019-05-30 |
US20180153921A1 (en) | 2018-06-07 |
IL266862B2 (en) | 2024-01-01 |
RU2019120040A (ru) | 2021-01-11 |
IL266862A (en) | 2019-07-31 |
RU2019120040A3 (es) | 2021-04-09 |
CA3043635A1 (en) | 2018-06-07 |
JP2020500526A (ja) | 2020-01-16 |
US20230270774A1 (en) | 2023-08-31 |
EP3548616A4 (en) | 2020-05-13 |
EP3548616A1 (en) | 2019-10-09 |
JP7292204B2 (ja) | 2023-06-16 |
US11504389B2 (en) | 2022-11-22 |
CN110214184A (zh) | 2019-09-06 |
AU2017367722A8 (en) | 2019-06-13 |
IL266862B1 (en) | 2023-09-01 |
KR20190085529A (ko) | 2019-07-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019006426A (es) | Reguladores de tau, y composiciones y metodos para su administracion. | |
MX2020003995A (es) | Nuevas moleculas de acido nucleico artificiales. | |
MX2021014955A (es) | Formulaciones subcutaneas de anticuerpos anti-cd38 y sus usos. | |
MX2019007480A (es) | Anticuerpos monoclonales anti-alfa-sinucleina para prevenir la agregacion de tau. | |
CR20230163A (es) | ANTICUERPOS ANTITAU Y MÉTODOS DE USO (Divisional 2019-0271) | |
MX2018007304A (es) | Composiciones de interleucina-15 y sus usos. | |
MX2021009309A (es) | Modulacion de la actividad del complemento. | |
MX2019013670A (es) | Formulaciones de anticuerpos y proteinas. | |
SG10201808063PA (en) | Compositions for modulating ataxin 2 expression | |
MX2019006330A (es) | Anticuerpos anti-tau y metodos de uso. | |
MA40902A (fr) | Vaccins hpv16 thérapeutiques | |
MX2017004473A (es) | Formulaciones de betalactamasa y usos de las mismas. | |
MX2019003805A (es) | Activadores de flujo autofágico y fosfolipasa d y depuración de acumulaciones de proteína que incluyen tau y tratamiento de proteinopatías. | |
MX2020004666A (es) | Compuestos de pilocarpina con ácido lipoico para el tratamiento de trastornos oculares. | |
GEP20196961B (en) | 4-oxo-3,4-dihydro-1,2,3 -benzotriazines modulators of gpr139 | |
MX2017009417A (es) | Formas solidas de acido 2-(5-(3-fluorofenil)-3-hidroxipicolinamido )acetico, composiciones y usos de las mismas. | |
MX2019004859A (es) | Tratamientos de combinacion que comprenden la administracion de imidazopirazinonas. | |
WO2014145485A3 (en) | Map kinase modulators and uses thereof | |
MX2017003121A (es) | Formulaciones de anticuerpos. | |
SG10201808278TA (en) | Polishing composition and polishing method | |
MX2018011875A (es) | Reprogramacion cardiaca directa mejorada. | |
MX2021006945A (es) | Anelosomas para suministrar modalidades terapéuticas de reemplazo de proteínas. | |
MY184878A (en) | Compositions and methods for treating neurodegenerative diseases | |
MX2016017025A (es) | Formulaciones de proteinas. | |
MA39347A1 (fr) | Protéines de fusion d'uti |